INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (INVO) on October 1, 2024, reporting events that occurred on September 25, 2024. The Company, incorporated in Nevada and trading on The Nasdaq Stock Market, operates in the fertility sector.
Key Financial Metrics and Transaction Details
The filing details a specific financing transaction rather than periodic financial results. Key metrics from the transaction include:
- Transaction Type: Standard Merchant Cash Advance Agreement.
- Future Sales Purchased: $384,250.
- Gross Purchase Price: $265,000.
- Net Proceeds Received: $251,750.
- Repayment Terms: $9,606 per week until the purchase price is repaid.
- Use of Proceeds: Working capital and general corporate purposes.
The filing does not provide current revenue, profit, cash flow, margins, or total debt figures outside of this specific transaction.
Material Changes and Debt Obligations
The Company entered into a new direct financial obligation via the Merchant Cash Advance. Additionally, the Company secured approval from its senior secured lender, Decathlon Alpha V, L.P. ("Decathlon"), to consummate this transaction. This approval was granted pursuant to an Amended and Restated First Amendment to the Revenue Loan and Security Agreement dated September 29, 2023.
A material condition was added to the existing Decathlon agreement: the minimum interest multiples will automatically increase by 0.15x as of December 1, 2024, unless the Company receives equity investments totaling at least $1,000,000 by November 30, 2024. The Buyer in the new transaction has subordinated its rights to those of Decathlon.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds of $251,750 for working capital. The primary risk highlighted in the filing is the potential increase in interest multiples on the existing Decathlon loan if the Company fails to raise $1,000,000 in equity by the November 30, 2024 deadline. The filing does not provide specific forward-looking guidance on revenue or earnings.
Key Facts for Investor Verification
- Verify the Company's ability to raise $1,000,000 in equity by November 30, 2024, to avoid an automatic 0.15x increase in interest multiples on the Decathlon loan.
- Confirm the impact of the new weekly repayment obligation of $9,606 on the Company's weekly cash flow.
- Review the subordination agreement to understand the priority of claims between the new Buyer and Decathlon Alpha V, L.P.
- Monitor the Company's cash burn rate given the reliance on merchant cash advances for working capital.